Works matching IS 02692813 AND DT 2023 AND VI 58 AND IP 6
Results: 15
Editorial: Recent advances in fibrosis assessment for metabolic dysfunction‐associated fatty liver disease–Authors' reply.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Editorial: If STRIDE‐II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails—Authors' reply.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Letter: Chinese herbal medicine Curcumin–QingDai (CurQD)—A good treatment option for active ulcerative colitis? Authors' reply.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Recent advances in fibrosis assessment for metabolic dysfunction‐associated fatty liver disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 6, p. 636, doi. 10.1111/apt.17651
- By:
- Publication type:
- Article
Letter: Chinese herbal medicine Curcumin‐QingDai (CurQD) – A good treatment option for active ulcerative colitis?
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short‐term aspirin use.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 6, p. 562, doi. 10.1111/apt.17646
- By:
- Publication type:
- Article
AutoFibroNet: A deep learning and multi‐photon microscopy‐derived automated network for liver fibrosis quantification in MAFLD.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 6, p. 573, doi. 10.1111/apt.17635
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 6, p. 559, doi. 10.1111/apt.17025
- Publication type:
- Article
Editorial: If STRIDE‐II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 6, p. 585, doi. 10.1111/apt.17637
- By:
- Publication type:
- Article
Letter: Baveno‐VI criteria to exclude large varices in patients with hepatocellular carcinoma—What have we learned?
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 6, p. 642, doi. 10.1111/apt.17636
- By:
- Publication type:
- Article
Effect of different PD‐1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 6, p. 611, doi. 10.1111/apt.17623
- By:
- Publication type:
- Article
Non‐resolution of acute kidney injury in the first week portends the development of chronic kidney disease in critically ill patients with cirrhosis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 6, p. 593, doi. 10.1111/apt.17639
- By:
- Publication type:
- Article
The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 6, p. 623, doi. 10.1111/apt.17638
- By:
- Publication type:
- Article
Featured Cover.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 6, p. i, doi. 10.1111/apt.17024
- By:
- Publication type:
- Article